Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Detail) - Operating results of the reportable segments

v2.4.0.6
Segment reporting (Detail) - Operating results of the reportable segments (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Oct. 31, 2012
Oct. 31, 2011
Clinical laboratory services $ 15,177 $ 14,187
Product revenues 8,434 9,704
Royalty and license fee income 2,019 1,862
Revenue net 25,630 25,753
Cost of clinical laboratory services 9,710 8,814
Cost of product revenues 4,184 5,137
Research and development 1,011 1,625
Selling, general and administrative 11,415 12,385
Provision for uncollectible accounts receivable 1,594 1,286
Legal 1,700 868
Total operating expenses 29,614 30,115
Operating (loss) income (3,984) (4,362)
Interest (9) (2)
Other 9 9
Foreign exchange gain 229 29
Income (loss) before income taxes (3,755) (4,326)
Depreciation and amortization included above 1,149 1,222
Share-based compensation included in above:    
Share-based compensation 142 213
Capital expenditures 291 252
Clinical Labs [Member] | Cost of Clinical Laboratory Services [Member]
   
Share-based compensation included in above:    
Share-based compensation 2 2
Clinical Labs [Member] | Selling, General and Administrative Expenses [Member]
   
Share-based compensation included in above:    
Share-based compensation 11 13
Clinical Labs [Member]
   
Clinical laboratory services 15,177 14,187
Revenue net 15,177 14,187
Cost of clinical laboratory services 9,710 8,814
Research and development 89 44
Selling, general and administrative 4,961 4,831
Provision for uncollectible accounts receivable 1,556 1,273
Legal 107 43
Total operating expenses 16,423 15,005
Operating (loss) income (1,246) (818)
Interest (9) (1)
Other 6 5
Income (loss) before income taxes (1,249) (814)
Depreciation and amortization included above 308 266
Share-based compensation included in above:    
Share-based compensation 13 15
Capital expenditures 205 215
Life Sciences [Member] | Research and Development Expense [Member]
   
Share-based compensation included in above:    
Share-based compensation 1 3
Life Sciences [Member] | Selling, General and Administrative Expenses [Member]
   
Share-based compensation included in above:    
Share-based compensation   20
Life Sciences [Member]
   
Product revenues 8,434 9,704
Royalty and license fee income 2,019 1,862
Revenue net 10,453 11,566
Cost of product revenues 4,184 5,137
Research and development 606 1,048
Selling, general and administrative 4,272 5,228
Provision for uncollectible accounts receivable 38 13
Legal 6 383
Total operating expenses 9,106 11,809
Operating (loss) income 1,347 (243)
Interest (1) (1)
Other 1 (5)
Foreign exchange gain 229 29
Income (loss) before income taxes 1,576 (220)
Depreciation and amortization included above 813 914
Share-based compensation included in above:    
Share-based compensation 1 23
Capital expenditures 86 30
Therapeutics [Member]
   
Research and development 316 533
Total operating expenses 316 533
Operating (loss) income (316) (533)
Income (loss) before income taxes (316) (533)
Depreciation and amortization included above 7 11
All Other Segments [Member] | Selling, General and Administrative Expenses [Member]
   
Share-based compensation included in above:    
Share-based compensation 128 175
All Other Segments [Member]
   
Selling, general and administrative 2,182 2,326
Legal 1,587 442
Total operating expenses 3,769 2,768
Operating (loss) income (3,769) (2,768)
Interest 1  
Other 2 9
Income (loss) before income taxes (3,766) (2,759)
Depreciation and amortization included above 21 31
Share-based compensation included in above:    
Share-based compensation 128 175
Capital expenditures   7
Cost of Clinical Laboratory Services [Member]
   
Share-based compensation included in above:    
Share-based compensation 2 2
Research and Development Expense [Member]
   
Share-based compensation included in above:    
Share-based compensation 1 3
Selling, General and Administrative Expenses [Member]
   
Share-based compensation included in above:    
Share-based compensation $ 139 $ 208